0
0
- Plan sets out the partnership’s key priorities and ways of working, as countries transition to managing COVID-19 as a long-term public health issue
- The plan’s focus is on vaccinating high-risk populations, introducing new treatments, boosting testing and securing sustained access to COVID-19 tools
- The Access to COVID-19 Tools Accelerator is a global collaboration to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines.
The Access to COVID-19 Tools (ACT) Accelerator today launches its plan for the next six months, setting out how, as a partnership of global health agencies working alongside government, civil society and other partners, it will support countries as the world transitions to long-term COVID-19 control.
Recognizing the evolving nature of the COVID-19 virus and pandemic, the plan outlines changes to ACT-A’s set-up and ways of working, to ensure countries continue to have access to COVID-19 tools in the longer term, while maintaining the coalition’s readiness to help address future disease surges.
Developed through a consultative process with ACT-A agencies, donors, industry partners, civil society organizations (CSOs) and Facilitation Council members, the plan summarizes priority areas of focus for the partnership’s pillars, coordination mechanisms and other core functions, and highlights the work to be maintained, transitioned, sunset, or kept on standby. The transition plan supports the work of ACT-A agencies as they evolve the financing, implementation and mainstreaming of their COVID-19 efforts.
The next phase of ACT-A partners’ work will centre on three overarching areas:
- Focusing research and development (R&D) and market shaping activities to ensure a pipeline for new and enhanced COVID-19 tools
- Securing institutional arrangements for sustained access for all countries to COVID-19 vaccines, tests and treatments, including oxygen
- Concentrating in-country work on new product introduction (e.g., new oral antivirals for those at highest risk) and protection of priority populations (e.g., full vaccination of health care workers and older populations), in support of national and international targets
“As the world moves towards managing COVID-19 over the long-term, ACT-A will continue to support countries by providing access to vaccines, tests, and treatments,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. “But as this plan lays out, we still have a lot of work to do to achieve equitable access to these life-saving tools, with health workers and at-risk populations as our top priority.”
Other changes outlined in the plan include the transition to a new ACT-A Tracking and Monitoring Taskforce, co-chaired by senior officials of India and the US, with the political-level Facilitation Council going into ‘standby’ mode, with the capacity to reactivate if needed due to a surge in severe disease.
ACT-A agencies have driven resource mobilization efforts and this plan sets out the shift to mainstream partnership-level financing and resource mobilization into the regular work of each agency going forward. Based on the three over-arching areas of work outlined above, existing financial commitments and country demand for tools, the ACT-A agencies require an estimated US$400 million for their transition work over the next six months. The ACT-A hub will continue to provide a transparent view of ACT-A agencies’ financing situation during this period.
The ACT-Accelerator is the world’s only end-to-end solution for accelerating the development of, and equitable access to, COVID-19 vaccines, tests and treatments. This partnership has played a key role in facilitating access to COVID-19 countermeasures for low- and lower-middle-income countries throughout the pandemic, most notably:
- Providing more than 1.8 billion doses of vaccine to 146 countries and territories – including 75% of the vaccines deployed in low-income countries and the majority of doses supplied to Africa – through COVAX, the vaccines pillar led by CEPI, Gavi, WHO and UNICEF.
- Delivering over 161 million tests, more than halving the cost of rapid tests to under $1 per test, and supplying around 80% of tests used in Africa in the first year of the pandemic through the Diagnostics Pillar led by FIND and the Global Fund.
- Delivering over 40 million COVID-19 treatment courses, investing an unprecedented US$ 1 billion in expanding sustainable oxygen access in LMICs, and initiating the delivery of new antivirals, through the Therapeutics Pillar, led by the Global Fund, Unitaid and Wellcome.
- Delivering over 2 billion items of personal protective equipment (PPE), supporting health systems to deliver COVID-19 tools, and boosting their laboratory, waste management and treatment capacities, through the Health Systems and Response Connector, led by the Global Fund, WHO and the World Bank.
